#USA #New York #SueWallSt #Fractyl Health #GUTS

Fractyl Health, Inc. Faces Securities Class Action

Fractyl Health, Inc. (NASDAQ: GUTS) is currently embroiled in a securities class action lawsuit following a sharp decline in its stock prices. The lawsuit highlights alleged discrepancies in clinical data which stakeholders believe misled investors regarding the efficacy of the company's weight loss treatment, Revita.

On January 29, 2026, shares of Fractyl saw a staggering drop of 68.03%, closing at $0.585—down from a high of $1.83—subsequently declining further to $0.46 by January 30. According to the complaint, this drastic fall was initiated by investors who purchased the stock between January 13, 2025, and January 29, 2026.

Joseph E. Levi, Esq., representing the plaintiffs, claims this case raises serious questions about the transparency of clinical trial data shared with investors. The suit asserts that Fractyl’s promotional materials downplayed operational issues at one of its six REMAIN-1 Midpoint Cohort clinical trial sites, where higher-than-expected weight regain was reported. This inconsistency had a material impact on the study's reported outcomes, crucially affecting the perceived success of the Revita DMR system.

Key findings revealed that out of the six Midpoint Cohort sites, one site acted as an outlier, with results indicating a 4.5% weight regain in patients treated with Revita. In contrast, a sham control group experienced a 7.5% weight regain. This single site’s performance skewed the overall trial results, as it failed to implement adequately robust dietary and lifestyle counseling programs, contributing to a misleading representation of the system’s effectiveness.

Market observers have noted a drastic shift in investor confidence regarding Fractyl following the release of the REMAIN-1 Midpoint data. Morgan Stanley, after analyzing the data, reduced their projected success rate for the Revita system from 50% to 35%, and lowered the stock price target from $8.00 to $2.00. The plaintiffs are now seeking recovery for their losses resulting from what they consider inflated stock prices based on misleading clinical data.

Details of the Allegations

The complaint asserts that:

• - Fractyl Health issued materially false statements regarding the Revita DMR System and the integrity of its clinical trials.
• - The company misleadingly represented the trial's execution, including overlooking significant data from the outlier clinical site which undermines the credibility of its weight loss claims.
• - Key changes in treatment outcomes were not disclosed adequately, impacting investor decisions.

How Investors Can Proceed

Investors believing they may be affected are encouraged to gather and submit any relevant share purchase records for evaluation. This step is crucial for potentially participating in any future recovery efforts. The deadline for individuals to apply for lead plaintiff status is October 20, 2026, but class members who do not do so can still benefit from any recovery.

For those who might have already sold their shares, it is worth noting that eligibility for claims extends to all buyers during the class period, irrespective of their current shareholding status. To facilitate recovery actions, submission of documentation such as brokerage statements or trade confirmations is recommended.

Conclusion

As the case unfolds, many stakeholders within the investor community are watching closely, with implications not just for Fractyl Health's current position but also for the overall integrity of clinical data reporting in the pharmaceutical landscape. Participants in this ongoing situation are urged to consult with financial and legal advisors to navigate the complexities that lie ahead. Ensuring transparent communication and ethical reporting in clinical trials remains critical to uphold investor trust in the health sector.